
|Articles|December 13, 2013
The Utility of the BRCAvantage Test
Author(s)Sukumar Nagendran, MD
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Advertisement
Clinical Pearls
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
- BRCAvantage was launched in mid-October
- The test is a comprehensive solution to help patients and healthcare providers make clinical decisions regarding the prognostic nature of their disease course and treatment interventions
- BRCAvantage includes a complete analysis of BRCA1 and BRCA2 as well as targeted tests for other specific gene mutations and family gene mutations
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5









































